E-Sisters from across the country gathered on Tuesday, July 17, 2018 at medical device manufacturer Bayer’s New Jersey headquarters to demand an Essure recall in-person, ABC8 reports.

E-Sisters Rally Around New Netflix Documentary

Holding signs reading “Boycott Bayer” and “#Recall Essure,” the E-Sisters rallied outside of Bayer’s Whippany home base all day, as Bayer employees were invited to join them on the lawn to watch a pre-release screening of The Bleeding Edge, a new Netflix-produced documentary about the medical device industry and the dangers of untested high-risk medical devices.

Surgical Operation

Featuring testimony from a number of E-Sisters, women who have been drawn together by their horrific experiences with Essure, The Bleeding Edge captures a medical device industry on the fringes of federal regulation, a Wild West where device manufacturers like Bayer often release dangerous products onto the market without any clinical safety or efficacy testing. The film focuses on the lives ruined by high-risk medical devices, portraying a terrifying and normally-unseen landscape of human suffering.

A statement from The Bleeding Edge reads:

Today, we saw the grassroots power of women like the Essure Problems E-Sisters fighting for Bayer to recall its harmful Essure sterilization implant. Outside of Bayer’s headquarters, they rallied and screened the upcoming Netflix Original The Bleeding Edge to expose how the $400 billion medical device industry makes some implants that threaten – instead of improve – our quality of life. To add insult to injury, while medical implant companies like Bayer are being sued by tens of thousands, they are paying doctors to promote their dangerous products. These aren’t isolated cases – it’s systemic.

The Bleeding Edge will be released on Netflix July 27, 2018.

Bayer Fires Back At “Misinformation”

Naturally, Bayer struck out against the E-Sisters in a press statement released after the protest, writing:

As a leader in women’s healthcare, Bayer believes strongly that women and their physicians should make reproductive health decisions based on sound science. Over the last 20 years, Essure has been studied by Bayer and independent medical professionals in more than 200,000 patients, both in pre- and post-approval studies, and this extensive body of scientific evidence establishes that Essure is comparable in safety and effectiveness to tubal ligation – an invasive surgical procedure that is the only other option for women who desire permanent birth control.

“We are increasingly concerned with the continued spread of misinformation that may scare women with Essure to seek removal, which can lead to serious and unnecessary surgery, as well as post-operative complications. It is important that women speak with their doctor any time they have concerns or questions about a product or procedure and we encourage women who have questions or concerns about Essure to seek proper medical advice from an experienced, board-certified Obstetrician-Gynecologist.

Bayer’s protestations are, in some sense, too little too late. On the global market, Essure has already been defeated. In the face of mounting public pressure, Bayer voluntarily pulled the medical device from every market outside the United States in September 2017.

Early this year, the FDA ramped up its regulations on Essure, prohibiting use of the device unless physicians thoroughly discuss the implant’s risks with patients and receive their signatures for consent.